Drugs / Lactobacillus
Lactobacillus
also known as
Bifidobacterium lactis · Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) · live combined Bifidobacterium and Lactobacillus · B. lactis · Bifidobacterium animalis ssp. lactis · Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live · live combined Bifidobacteriun, Lactobacillus and Enterococcus · Live Probiotic tablet
Trials 11
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2018-05-10 | Lallemand Pharma AG | Regulatory B. lactis LAFTI® B94 and L. helveticus LAFTI® L10 recognized for their health benefits by Health Canada lallemand.com ↗
Lallemand Health Solutions is pleased to announce that its documented probiotic strain Bifidobacterium animalis ssp. lactis LAFTI® B94 has been recognized by the Canadian Health Authorities for its gut health benefits in children, adolescents, and adults. |
| 2017-06-12 | Lallemand Pharma AG | Results Publication of a safety and tolerance study for ProbioKid® strains in infants lallemand.com ↗
No serious adverse events were reported and the Spanish authors concluded that the use of the three probiotic strains in infancy is safe, and well tolerated. |
| 2017-05-29 | Lallemand Pharma AG | Regulatory ProbioKid® and its specific probiotic strains recognized safe in both the US and Canada for use in young children lallemand.com ↗
A panel of independent renowned experts in the field of probiotics confirmed the GRAS status for infants and children while Health Canada approved the formula for children from 3 months old. |
| 2017-02-27 | Winclove Probiotics B.V. | Results Probiotic supplements beneficially affect Tryptophan–Kynurenine Metabolism wincloveprobiotics.com ↗
The ratio of subjects taking the placebo who experienced one or more URTI symptoms was increased 2.2-fold compared to those on probiotics (PLA 0.79, PRO 0.35; p = 0.02). |
| 2016-04-11 | Lallemand Pharma AG | Regulatory Probio’Stick: the first and only probiotic with approved health claims in the gut-brain axis area in Canada lallemand.com ↗
The Natural and Non-prescription Health Products Directorate (NNHPD), the regulatory agency for natural health products in Canada, has approved the following new strong claims for Probio’Stick (Claim NPN 80021343): |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-05-10 | Lallemand Pharma AG | B. lactis LAFTI® B94 and L. helveticus LAFTI® L10 recognized for their health benefits by Health Canada lallemand.com ↗ |
| 2017-06-12 | Lallemand Pharma AG | Publication of a safety and tolerance study for ProbioKid® strains in infants lallemand.com ↗ |
| 2017-05-29 | Lallemand Pharma AG | ProbioKid® and its specific probiotic strains recognized safe in both the US and Canada for use in young children lallemand.com ↗ |
| 2017-02-27 | Winclove Probiotics B.V. | Probiotic supplements beneficially affect Tryptophan–Kynurenine Metabolism wincloveprobiotics.com ↗ |
| 2016-04-11 | Lallemand Pharma AG | Probio’Stick: the first and only probiotic with approved health claims in the gut-brain axis area in Canada lallemand.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus | “One capsule of cranberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU per day for 10 days” NCT06788132 ↗6“Target isolation and culture of core beneficial bacteria (Lactobacillus and Bifidobacterium)” NCT07188909 ↗ |
| Known as | B. lactis | “Active was a strawberry yogurt-based drink supplemented with Bifidobacterium animalis ssp. lactis (B. lactis) BB-12.” PMID 20216564 ↗ Mar 2010 |
| Known as | Bifidobacterium animalis ssp. lactis | “Active was a strawberry yogurt-based drink supplemented with Bifidobacterium animalis ssp. lactis (B. lactis) BB-12.” PMID 20216564 ↗ Mar 2010 |
| Known as | Bifidobacterium lactis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00492583 ↗ |
| Known as | Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live | “Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live)” NCT06960369 ↗ |
| Known as | Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05220124 ↗ |
| Known as | live combined Bifidobacterium and Lactobacillus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03556631 ↗ |
| Known as | live combined Bifidobacteriun, Lactobacillus and Enterococcus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05901779 ↗ |
| Known as | Live Probiotic tablet | “Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live)” NCT06960369 ↗ |
| Action | Activate | “oral administration of lactobacillus can boost NK-T cell activity in children with HIV without side effects” NCT00011141 ↗ |
| Modality | Other / unclassified | “live combined Bifidobacterium and Lactobacillus preparation” NCT03556631 ↗ |
| Route | Oral | “Oral lactobacillus administration” NCT00011141 ↗ |